Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Peng-hui Luo"'
Autor:
Dun-Chang Mo, Jian-Feng Huang, Peng Lin, Shang-Xiao Huang, Han-Lei Wang, Peng-Hui Luo, Xiu-Juan Liang
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Background: The use of immune checkpoint inhibitors (ICIs) as neoadjuvant therapy is a promising novel approach in resectable non-small-cell lung cancer (NSCLC). This study aimed to investigate the prognostic value of PD-L1 in patients with
Externí odkaz:
https://doaj.org/article/b8856f97a7b04cef84e5866486c8acbc
Autor:
Yao-Ning Feng, Guang-Yu Xie, Li Xiao, Dun-Chang Mo, Jian-Feng Huang, Peng-Hui Luo, Xiu-Juan Liang
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionImmune checkpoint inhibitor (ICI) combination therapy has changed the treatment landscape for metastatic renal cell carcinoma (mRCC). However, little evidence exists on the treatment-related severe adverse events (SAEs) and fatal adverse
Externí odkaz:
https://doaj.org/article/e17634d0d7c94f6e8158f0d7429e8ce1
Publikováno v:
European Archives of Oto-Rhino-Laryngology. 280:1-9
This study aimed to evaluate the efficacy and safety of programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) inhibitor plus chemotherapy vs standard of care (SoC) treatment in the first-line treatment for recurrent or metastatic head a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c57674125a221d0cdcc21ae287c5fd3
https://doi.org/10.1007/s00405-022-07571-9
https://doi.org/10.1007/s00405-022-07571-9
Publikováno v:
JAMA Oncology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::471995c02623bb9b3d14c9059be17708
https://doi.org/10.1001/jamaoncol.2023.1388
https://doi.org/10.1001/jamaoncol.2023.1388
Publikováno v:
Investigational New Drugs. 40:810-817
To evaluate the efficacy and safety of immune checkpoint inhibitor (ICI) and chemotherapy (CT) versus CT alone in advanced non-small-cell lung cancer (NSCLC).Databases (PubMed, Embase and Cochrane Library) were searched for relevant randomized contro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::709bc655cf5bff2b89851222803c0335
https://doi.org/10.1007/s10637-022-01232-8
https://doi.org/10.1007/s10637-022-01232-8
Publikováno v:
Journal of Clinical Oncology. 41:2667-2668
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9e1e34d88a2820e6ffca3712f8fe66c
https://doi.org/10.1200/jco.22.02665
https://doi.org/10.1200/jco.22.02665
Publikováno v:
Experimental and Therapeutic Medicine. 24
Anti-programmed cell death protein-1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) antibodies have been widely used in cancers. The present study aimed to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in human cancers. Studies were sear
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6a388a06f8e4e8b6855c3443dd6f470
https://doi.org/10.3892/etm.2022.11685
https://doi.org/10.3892/etm.2022.11685
Publikováno v:
The Lancet. Oncology. 24(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a6d90e09414cbdf5ebf595bd55432a2
https://pubmed.ncbi.nlm.nih.gov/36603930
https://pubmed.ncbi.nlm.nih.gov/36603930
Publikováno v:
Medicine. 101(38)
This study aimed to evaluate the efficacy of immune checkpoint inhibitors (ICIs) as maintenance therapy for advanced or metastatic cancers.The PubMed, Embase, and Cochrane Library databases were searched for eligible randomized controlled trials. A m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a6b8a15121bdd1f812277a0d960b807
https://pubmed.ncbi.nlm.nih.gov/36197237
https://pubmed.ncbi.nlm.nih.gov/36197237
Publikováno v:
The Lancet Oncology. 24:e230
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c54c8b9a303d7bc97ecdaed83dc1d9be
https://doi.org/10.1016/s1470-2045(23)00211-5
https://doi.org/10.1016/s1470-2045(23)00211-5